SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 in Boston, Massachusetts
- Hosting 1×1 investor meetings only
Wells Fargo 2022 Healthcare Conference on Friday, September 9, 2022 at 8:35 AM ET in Boston, Massachusetts
- Participating in a fireside chat and hosting 1×1 investor meetings
Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 2:15 PM ET in New York, New York
- Participating in a fireside chat and hosting 1×1 investor meetings
Baird 2022 Global Health Conference on Tuesday, September 13, 2022 at 8:30 AM ET in New York, New York
- Participating in a fireside chat only
H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 10:00 AM ET in New York, New York
- Participating in a fireside chat only
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
